
Astrazeneca Pharma Poland sp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Astrazeneca Pharma Poland is a biopharmaceutical company that develops and manufactures medicines for major challenges in modern medicine. Its therapeutic areas include oncology, cardiovascular and metabolic diseases, respiratory diseases, autoimmune conditions, neurological diseases, infectious diseases and vaccines.
Financials
Revenue history (in m)
Financial insight
- The statement flags a going concern risk. N/A
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 52 days for 2023). All were audited by a statutory auditor.
- 202526/06/2026
- 202405/08/2025
- 202305/09/2024
- 202230/06/2023
- 202127/07/2022
- 202016/08/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Public procurement
4 tenders recorded as contractor, with a total value of $2,122,378.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Sep 3, 2026 | Supplementary tender for the supply to WCSKJ of medicinal products used in drug programmes and chemotherapy | $1.6M$1,625,878 | Wojewódzkie Centrum Szpitalne Kotliny Jeleniogórskiej | |
| Apr 14, 2026 | Purchase and supply of general hospital medicines for Samodzielny Publiczny Zakład Opieki Zdrowotnej w Puławach, divided into 83 lots. | $69,874$69,874 | Samodzielny Publiczny Zakład Opieki Zdrowotnej w Puławach | |
| Nov 19, 2025 | Supply of medicinal products from drug programmes and new medicinal products | $405K$404,979 | Copernicus Podmiot Leczniczy sp. z o.o. |
The company is the contractor in 99 public sector contracts, worth USD 17.06m in total. They were signed with 30 public buyers. The largest number (2) were signed with Uniwersyteckie Centrum Kliniczne.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Nov 13, 2026 | Purchase of medicines | $692.35 | Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Przasnyszu | |
| Nov 2, 2026 | Purchase of medicines/RDTL | $4,109 | Uniwersytecki Szpital Kliniczny Nr 1 Im. Prof. Tadeusza Sokołowskiego Pum w Szczecinie | |
| Oct 30, 2026 | Supply of medicinal products | $950.46 | Zakład Karny w Czarnem |
Trademarks
The company currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2003.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| KLUB INTENSYWISTÓW WARSZAWSKICH | Z.357649 | 16, 41, 44 | Expired | – | |
| WOLNOŚĆ ODDECHU (word) | Z.265520 | 5, 10, 35, 36, 39, 41, 44 | Expired | – |
| Mark | Protected until | |
|---|---|---|
| KLUB INTENSYWISTÓW WARSZAWSKICH | – | |
| WOLNOŚĆ ODDECHU (word) | – |
Authorized Representatives
Manner of representation
Each of the members of the management board is authorized to make declarations and sign documents on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Astrazeneca Continent B.v. | 4,000 | $540,248.51 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2003-10-01.
96 1030 1508 0000 0005 0287 6023
43 1030 1508 0000 0005 0287 6007
21 1030 1508 0000 0005 0287 6015
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 547.9KPLN 547,861 |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 31, 2025 | Aid for research and development projects: experimental development | $1.7M$1,687,095 | PIERWSZY MAZOWIECKI URZĄD SKARBOWY W WARSZAWIE |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Adamed Pharma S.A. | $541,927,181.76 | adamed.com.pl | ||
| Teva Operations Poland sp. z o.o. | $529,423,373.78 | teva.pl | ||
| Novartis Poland sp. z o.o. | $378,147,128.47 | novartis.com | ||
| Janssen-Cilag Polska sp. z o.o. | $323,933,929.12 | janssen.pl | ||
| Bristol-Myers Squibb Polska sp. z o.o. | $230,722,737.87 | bms.com | ||
| Takeda Pharma sp. z o.o. | $246,400,594.27 | takeda.com | ||
| Accord Healthcare Polska sp. z o.o. | $178,502,388.11 | accord-healthcare.pl | ||
| Gilead Sciences Poland sp. z o.o. | $150,844,944.19 | gilead.com | ||
| Chiesi Poland sp. z o.o. | $87,762,158.97 | chiesi.com | ||
| Solinea sp. z o.o. | $72,245,607.27 | solinea.pl |
Change history
| Date | Event | |
|---|---|---|
| 2015-12-29 | Address change (Postępu 18, 02-676, Warszawa → Ul. Postępu 14, 02-676, Warszawa) | |
| 2007-01-02 | Address change (Domaniewska 41, 02-672, Warszawa → Postępu 18, 02-676, Warszawa) | |
| 2003-11-25 | Share capital increase (50,000.00 PLN → 2,000,000.00 PLN) | |
| 2003-10-09 | Address change (Mineralna 15, 02-274, Warszawa → Domaniewska 41, 02-672, Warszawa) | |
| 2002-08-19 | Address change (Krucza 16/22, 00-526, Warszawa → Mineralna 15, 02-274, Warszawa) |
FAQ
Last updated: 2026-10-07